American Journal of Ophthalmology
Volume 143, Issue 6 , Pages 958-969.e2 , June 2007

Surveillance of the Eye and Vision in Clinical Trials of CP-675,206 for Metastatic Melanoma

  • Bradley R. Straatsma

      Affiliations

    • Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California
    • Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California
    • Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California
    • Corresponding Author InformationInquiries to Bradley R. Straatsma, Department of Ophthalmology and Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, 100 Stein Plaza, Los Angeles, CA 90095
    • ,
  • Steven Nusinowitz

      Affiliations

    • Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California
    • Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California
    • ,
  • Tara A. Young

      Affiliations

    • Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California
    • Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California
    • Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California
    • ,
  • Lynn K. Gordon

      Affiliations

    • Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California
    • Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California
    • ,
  • Melissa W. Chun

      Affiliations

    • Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California
    • Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California
    • ,
  • Colleen Rosen

      Affiliations

    • Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California
    • ,
  • Elisabeth Seja

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California
    • ,
  • James S. Economou

      Affiliations

    • Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, California
    • Department of Microbiology, Immunology and Mole Genetics, University of California, Los Angeles, Los Angeles, California
    • Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California
    • ,
  • John A. Glaspy

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California
    • Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California
    • ,
  • Viviana Bozon

      Affiliations

    • Pfizer Global Research and Development, New London, Connecticut.
    • ,
  • Jesus Gomez-Navarro

      Affiliations

    • Pfizer Global Research and Development, New London, Connecticut.
    • ,
  • Antoni Ribas

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California
    • Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, California
    • Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California

,Accepted 16 February 2007.

References 

  1. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854
  2. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7–17
  3. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature. 2001;411:380–384
  4. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053
  5. Blansfield JA, Beck KE, Tran K, Yan JC, Hughes MS, Kammula US, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593–598
  6. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T-lymphocyte-associated antigen-4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100:4712–4717
  7. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–8977
  8. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741–750
  9. Robinson MR, Chan CC, Yang JC, Rubin BL, Gracia GJ, Sen HN, et al. Cytotoxic T- lymphocyte-associated antigen-4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004;27:478–479
  10. Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy JA, Economou JS, et al. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control Clin Trials. 2004;25:400–407
  11. US National Institutes of Health. Common Toxicity Criteria, Version 2.0. Available at: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf. Accessed Date: September 26, 2006.
  12. Ribas A, Comin-Anduix B, Bozon V. Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb CP-675,206. J Clin Oncol. 2006;24:Abstract 8033
  13. Collaborative Ocular Melanoma Study Group. COMS manual of procedures. Springfield, Virginia: National Technical Information Service; 1995;(accession no. PB95-179693)
  14. US National Institutes of Health. The National Eye Institute 25-item Visual Function Questionnaire (VFQ-25), Version 2000. Available at: http://www.nei.nih.gov/index.html. Accessed Date: September 26, 2006.
  15. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Flemming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484–1491
  16. Gogas H, Ioannovich J, Dafni U, Stavropoulu-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–718
  17. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–246
  18. Borkowski LM, Grover S, Fishman GA, Jampol LM. Retinal findings in melanoma-associated retinopathy. Am J Ophthalmol. 2001;132:273–275
  19. Tsao H, Millman P, Linette GP, et al. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol. 2002;138:799–802
  20. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6:S55–S57
  21. Gass JDM. Normal macula. In: 4th edn. Stereoscopic atlas of macular diseases diagnosis and treatment. Volume 1:St Louis, Missouri: Mosby; 1997;p. 1–18
  22. Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003;48:12–38
  23. Kellner U, Bornfeld N, Foerster MH. Severe course of cutaneous melanoma associated paraneoplastic retinopathy. Br J Ophthalmol. 1995;79:746–752
  24. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuro-ophthalmol. 2001;21:173–187
  25. Zacks DN, Pinnolis MK, Berson EL, Gragoudas ES. Melanoma-associated retinopathy and recurrent exudative retinal detachments in a patient with choroidal melanoma. Am J Ophthalmol. 2001;132:578–581
  26. Alexander KR, Barnes CS, Fishman GA, Milam AH. Nature of the cone ON-pathway dysfunction in melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 2002;43:1189–1197
  27. Lei B, Bush RA, Milam AH, Sieving PA. Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo. Invest Ophthalmol Vis Sci. 2000;41:262–266
  28. Potter MJ, Adamus G, Szabo SM, Lee R, Mohaseb K, Behn D, et al. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol. 2002;134:128–130
  29. Ladewig G, Reinhold U, Thirkill CE, Kerber A, Tilgen W, Pfohler C, et al. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br J Dermatol. 2005;152:931–938

PII: S0002-9394(07)00201-2

doi: 10.1016/j.ajo.2007.02.035

American Journal of Ophthalmology
Volume 143, Issue 6 , Pages 958-969.e2 , June 2007

Article Tools

* Image Usage & Resolution